https://www.businessline.global/boehringer-ingelheim-receives-positive-chmp-opinion-for-use-of-pradaxa-dabigatran-etexilate-for-the-treatment-and-prevention-of-venous-thromboembolic-events-in-children-from-birth-to-less-than/press-release/